ArticleCureus2025
Hyperkalemia Versus Pseudohyperkalemia Without ECG Changes in Acute Blast Crisis Progressing to Tumor Lysis Syndrome.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hyperkalemia is critical to recognize, but distinguishing it from pseudohyperkalemia is essential to avoid unnecessary treatment. We present a 66-year-old male with a history of myeloproliferative disorder and chronic myelomonocytic leukemia (CMML) who developed hyperleukocytosis (white blood cell (WBC) 666 × 10⁹/L, 95% blasts) and severe hyperkalemia (9.4 mmol/L) without electrocardiogram (ECG) changes. Pseudohyperkalemia was considered but ruled out by measuring serum and plasma potassium levels along with using heparinized and non-heparinized tubes. Pseudohyperkalemia is more common in hematologic malignancies due to extreme leukocytosis, which leads to an increase in cell fragility and potassium leakage during sample handling. Despite initial medical therapy, hyperkalemia persisted, requiring emergent hemodialysis, leukapheresis, and cytoreductive treatment. He developed tumor lysis syndrome (TLS), necessitating rasburicase and continuous renal replacement therapy. This case underscores the challenges of hyperkalemia in hematologic malignancies and the importance of rapid differentiation from pseudohyperkalemia.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.